← Back to Search

Deep Brain Stimulation

Deep Brain Stimulation for Obsessive-Compulsive Disorder (Phase Ib Trial)

N/A
Waitlist Available
Led By Wayne Goodman, MD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Failed an adequate trial of CBT for OCD, defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist
Male or female between ages 21 and 70
Must not have
Any neurological disorders (i.e., MS, Parkinson's Disease, seizure disorders, etc.) or evidence of brain abnormalities/injury, such as tumor, stroke, or traumatic brain injury
Timeline
Screening 3 weeks
Treatment Varies
Follow Up [time frame: month 18]
Awards & highlights
No Placebo-Only Group

Summary

This trial is for people with a hard-to-control form of OCD. The goal is to find a more reliable system for treating OCD by studying how to best place electrodes in the brain to deliver electrical stimulation.

Who is the study for?
This trial is for adults aged 21-70 with severe OCD that hasn't improved after trying many treatments, including cognitive-behavioral therapy and various medications. Participants must have a significant history of OCD symptoms causing distress and dysfunction. They cannot join if they have neurological disorders, high suicide risk, MRI contraindications, psychotic disorders like schizophrenia, or are pregnant.
What is being tested?
The study aims to develop an adaptive Deep Brain Stimulation (aDBS) system for patients with hard-to-treat OCD. It involves surgically implanting electrodes in the brain connected to a chest device that sends electrical currents to alter brain function. The Phase Ib will involve implanting the RC+S system in two subjects.
What are the potential side effects?
Potential side effects may include discomfort at the surgery site, infection risk from surgery, headache or pain related to stimulation adjustments, mood changes due to electrical current effects on the brain circuitry involved in emotion regulation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have completed 25 hours of a specific therapy for OCD without success.
Select...
I am between 21 and 70 years old.
Select...
I have completed 25 hours of a specific therapy for OCD without success.
Select...
I have had OCD for over 5 years that hasn't improved with treatment and affects my daily life.
Select...
I've tried and didn't respond to certain medications with added antipsychotics.
Select...
I have tried clomipramine without success.
Select...
I am between 21 and 70 years old.
Select...
I have had OCD for over 5 years that hasn't improved with treatment and affects my daily life.
Select...
I have tried at least three different SSRIs without success.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a neurological disorder or brain injury.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~[time frame: month 18]
This trial's timeline: 3 weeks for screening, Varies for treatment, and [time frame: month 18] for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hypomania
Obsessive-Compulsive Personality
Secondary study objectives
Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Rating OCD Symptom Severity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Summit RC+S DBS Implant for OCDExperimental Treatment1 Intervention
all subjects will receive surgical implantation of DBS system
Group II: One Month Blinded Discontinuation PeriodExperimental Treatment1 Intervention
The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform "sham" activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline

Find a Location

Who is running the clinical trial?

Carnegie Mellon UniversityOTHER
77 Previous Clinical Trials
539,892 Total Patients Enrolled
3 Trials studying Obsessive-Compulsive Disorder
19 Patients Enrolled for Obsessive-Compulsive Disorder
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,385 Previous Clinical Trials
652,685 Total Patients Enrolled
3 Trials studying Obsessive-Compulsive Disorder
5,007 Patients Enrolled for Obsessive-Compulsive Disorder
MedtronicIndustry Sponsor
619 Previous Clinical Trials
764,085 Total Patients Enrolled
5 Trials studying Obsessive-Compulsive Disorder
74 Patients Enrolled for Obsessive-Compulsive Disorder
University of PittsburghOTHER
1,792 Previous Clinical Trials
16,359,983 Total Patients Enrolled
6 Trials studying Obsessive-Compulsive Disorder
151 Patients Enrolled for Obsessive-Compulsive Disorder
Baylor College of MedicineLead Sponsor
1,028 Previous Clinical Trials
6,030,159 Total Patients Enrolled
15 Trials studying Obsessive-Compulsive Disorder
769 Patients Enrolled for Obsessive-Compulsive Disorder
Brown UniversityOTHER
466 Previous Clinical Trials
699,077 Total Patients Enrolled
8 Trials studying Obsessive-Compulsive Disorder
466 Patients Enrolled for Obsessive-Compulsive Disorder
Wayne Goodman, MDPrincipal InvestigatorBaylor College of Medicine
7 Previous Clinical Trials
158 Total Patients Enrolled
6 Trials studying Obsessive-Compulsive Disorder
148 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Summit RC+S System (Deep Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04281134 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Summit RC+S DBS Implant for OCD, One Month Blinded Discontinuation Period
Obsessive-Compulsive Disorder Clinical Trial 2023: Summit RC+S System Highlights & Side Effects. Trial Name: NCT04281134 — N/A
Summit RC+S System (Deep Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04281134 — N/A
~0 spots leftby Jun 2025